{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:06:54Z","timestamp":1786421214239,"version":"build-2736575974"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105226","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:32:17Z","timestamp":1771605137000},"page":"105226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Prognostic significance of circulating tumor DNA as a baseline or dynamic factor in advanced NSCLC without oncogenic drivers: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"221","author":[{"given":"M.E.","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Hedegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.W.C.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.B.","family":"Callesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.M.","family":"Szejniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ladekarl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Timm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.G.","family":"Spindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105226_bib1","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-18-1127","article-title":"Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer","volume":"79","author":"Anagnostou","year":"2019","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105226_bib2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/s41591-023-02226-6","article-title":"A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer","volume":"29","author":"Assaf","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.critrevonc.2026.105226_bib3","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1515\/cclm-2015-0776","article-title":"SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer","volume":"54","author":"Balgkouranidou","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.critrevonc.2026.105226_bib4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41698-024-00704-9","article-title":"Longitudinal liquid biopsy predicts clinical benefit from immunotherapy in advanced non-small cell lung cancer","volume":"8","author":"Boscolo Bragadin","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105226_bib5","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41416-022-01816-4","article-title":"Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis","volume":"127","author":"Callesen","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105226_bib6","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/1878-0261.13409","article-title":"Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC","volume":"17","author":"Carbonell","year":"2023","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105226_bib7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s43018-020-0043-5","article-title":"Circulating tumor DNA and liquid biopsy in oncology","volume":"1","author":"Cescon","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105226_bib8","doi-asserted-by":"crossref","first-page":"17836","DOI":"10.1002\/cam4.6108","article-title":"Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non-small cell lung cancer","volume":"12","author":"Cheng","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105226_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.31722","article-title":"Circulating tumor DNA and survival in metastatic breast cancer","volume":"7","author":"Dickinson","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105226_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00718","article-title":"Improving prediction of survival and progression in metastatic non-small cell lung cancer after immunotherapy through machine learning of circulating tumor DNA","author":"Ding","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105226_bib11","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.3390\/cancers14225649","article-title":"Maximum somatic allele frequency-adjusted blood-based tumor mutational burden predicts the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"14","author":"Dong","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105226_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105226_bib13","doi-asserted-by":"crossref","first-page":"33922","DOI":"10.18632\/oncotarget.15412","article-title":"Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"8","author":"Fan","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105226_bib14","series-title":"Global Cancer Observatory: Cancer Today [online]","author":"Ferlay","year":"2024"},{"key":"10.1016\/j.critrevonc.2026.105226_bib15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21873\/cgp.20319","article-title":"Combination of circulating tumour DNA and 18F-FDG PET\/CT for precision monitoring of therapy response in patients with advanced non-small cell lung cancer: a prospective study","volume":"19","author":"Fiala","year":"2022","journal-title":"Cancer Genom. Proteom."},{"key":"10.1016\/j.critrevonc.2026.105226_bib16","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/2767-9764.CRC-22-0258","article-title":"Circulating tumor DNA monitoring reveals molecular progression before radiologic progression in a real-life cohort of advanced non-small cell lung cancer patients","volume":"2","author":"Frank","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105226_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","article-title":"Oncogenic alterations in advanced NSCLC: a molecular super-highway","volume":"12","author":"Friedlaender","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.critrevonc.2026.105226_bib18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3390\/ijms26020611","article-title":"Circulating tumor cell-free DNA as prognostic biomarker in non-small cell lung cancer patients undergoing immunotherapy: the CORELAB experience","volume":"26","author":"Gelmini","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105226_bib19","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","article-title":"Genomic alterations and the incidence of brain metastases in advanced and metastatic NSCLC: a systematic review and meta-analysis","volume":"18","author":"Gillespie","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105226_bib20","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","article-title":"Early assessment of lung cancer immunotherapy response via circulating tumor DNA","volume":"24","author":"Goldberg","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105226_bib21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejca.2021.09.019","article-title":"Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis","volume":"158","author":"Gracie","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105226_bib22","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejca.2018.11.012","article-title":"A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology","volume":"106","author":"Haslam","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105226_bib23","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.critrevonc.2026.105226_bib24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/1878-0261.13330","article-title":"Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses\u2014the ComIT-1 trial","volume":"17","author":"Horndalsveen","year":"2023","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105226_bib25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2021.03.006","article-title":"Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival","volume":"149","author":"Jakobsen","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105226_bib26","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","article-title":"Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer","volume":"28","author":"Jee","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105226_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09971","article-title":"Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer","volume":"8","author":"Kapeleris","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.critrevonc.2026.105226_bib28","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41416-020-01047-5","article-title":"Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond","volume":"124","author":"Keller","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105226_bib29","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41591-022-01754-x","article-title":"Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial","volume":"28","author":"Kim","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105226_bib30","article-title":"Circulating tumor DNA evaluated by next-generation sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer","volume":"7","author":"Leprieur","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105226_bib31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40364-022-00400-5","article-title":"Blood-based tumour mutation index act as a prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients","volume":"10","author":"Lu","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.critrevonc.2026.105226_bib32","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1158\/1078-0432.CCR-22-0741","article-title":"Circulating tumor DNA kinetics predict progression-free and overall survival in EGFR TKI\u2013treated patients with EGFR-mutant NSCLC (SWOG S1403)","volume":"28","author":"Mack","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105226_bib33","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/1878-0261.12848","article-title":"KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer","volume":"15","author":"Mastoraki","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105226_bib34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","article-title":"REporting recommendations for tumour MARKer prognostic studies (REMARK)","volume":"93","author":"McShane","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105226_bib35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.critrevonc.2026.105226_bib36","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.3390\/cells9112514","article-title":"Detection of KRAS G12\/G13 mutations in cell free-DNA by droplet digital PCR, offers prognostic information for patients with advanced non-small cell lung cancer","volume":"9","author":"Michaelidou","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105226_bib37","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/1078-0432.CCR-23-1469","article-title":"Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer","volume":"30","author":"Murray","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105226_bib38","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.lungcan.2012.11.016","article-title":"The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer","volume":"79","author":"Nygaard","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105226_bib39","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1158\/1078-0432.CCR-23-1578","article-title":"Circulating tumor DNA monitoring on chemo-immunotherapy for risk stratification in advanced non-small cell lung cancer","volume":"29","author":"Pellini","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105226_bib40","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105226_bib41","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-18-0386","article-title":"Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab","volume":"24","author":"Raja","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105226_bib42","doi-asserted-by":"crossref","first-page":"9105","DOI":"10.1200\/JCO.2005.02.2905","article-title":"14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: the Spanish Lung Cancer Group","volume":"23","author":"Ramirez","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105226_bib43","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO-24-02347","article-title":"De-escalation strategies with immune checkpoint blockers in non-small cell lung cancer: do we already have enough evidence?","volume":"43","author":"Remon","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105226_bib44","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial","volume":"17","author":"Ren","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105226_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001504","article-title":"Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)","volume":"9","author":"Ricciuti","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105226_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.943253","article-title":"Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis","volume":"12","author":"S\u00e1nchez-Herrero","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105226_bib47","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105226_bib48","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12885-022-09421-7","article-title":"Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer\u2014is there a \u201ctail plateau\u201d in the survival curve of these patients?","volume":"22","author":"Shimamura","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105226_bib49","doi-asserted-by":"crossref","first-page":"971","DOI":"10.21037\/tlcr-22-818","article-title":"Blood tumor mutational burden and dynamic changes in circulating tumor DNA predict response to pembrolizumab treatment in advanced non-small cell lung cancer","volume":"12","author":"Stensgaard","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105226_bib50","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/PO.20.00321","article-title":"Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy","author":"Thompson","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105226_bib51","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/1878-0261.13090","article-title":"Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors","volume":"15","author":"van der Leest","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105226_bib52","doi-asserted-by":"crossref","first-page":"13390","DOI":"10.3390\/ijms241713390","article-title":"Detection and monitoring of tumor-derived mutations in circulating tumor DNA using the UltraSEEK lung panel on the MassARRAY system in metastatic non-small cell lung cancer patients","volume":"24","author":"van der Leest","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105226_bib53","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00372","article-title":"Changes in circulating tumor DNA reflect clinical benefit across multiple studies of patients with non\u2013small-cell lung cancer treated with immune checkpoint inhibitors","author":"Vega","year":"2022","journal-title":"JCO Precis. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105226_bib54","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1200\/PO.21.00182","article-title":"Dynamic changes of circulating tumor DNA predict clinical outcome in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors","author":"Weber","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105226_bib55","doi-asserted-by":"crossref","first-page":"855","DOI":"10.21037\/tlcr-20-826","article-title":"The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer","volume":"10","author":"Wen","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105226_bib56","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.3390\/cancers14102479","article-title":"Early assessment of chemotherapy response in advanced non-small cell lung cancer with circulating tumor DNA","volume":"14","author":"Yaung","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105226_bib57","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1111\/1759-7714.15098","article-title":"Prognostic and predictive impact of molecular tumor burden index in non-small cell lung cancer patients","volume":"14","author":"Yang","year":"2023","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105226_bib58","doi-asserted-by":"crossref","DOI":"10.1177\/03000605221093222","article-title":"Association between plasma somatic copy number variations and response to immunotherapy in patients with programmed death-ligand 1-negative non-small cell lung cancer","volume":"50","author":"Zhang","year":"2022","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.critrevonc.2026.105226_bib59","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41392-024-02087-6","article-title":"Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105226_bib60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41416-020-0833-7","article-title":"Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer","volume":"123","author":"Zulato","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105226_bib61","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1200\/PO.21.00057","article-title":"ctDNA predicts overall survival in patients with NSCLC treated with PD-L1 blockade or with chemotherapy","author":"Zou","year":"2021","journal-title":"JCO Precis. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:47:30Z","timestamp":1775908050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":61,"alternative-id":["S1040842826001137"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105226","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic significance of circulating tumor DNA as a baseline or dynamic factor in advanced NSCLC without oncogenic drivers: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105226","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105226"}}